Gilead makes Truvada, the only FDA-approved drug to prevent the transmission of HIV.
The agreement struck between Gilead and HHS will last until Dec. 31, 2025.
Truvada sells for about $1,600 to $2,000 a month in the U.S.
Gilead has faced criticism from AIDS activists who have pressured Gilead to make Truvada more widely available by breaking its patent or lowering its cost.
“Securing this commitment is a major step in the Trump administration’s efforts to use the prevention and treatment tools we have to end the HIV epidemic in America by 2030,” Mr. Azar said.
More articles on pharmacy:
8 recent pharmaceutical lawsuits, settlements
McKesson renews distribution deal with CVS Health
Sacklers discussed selling Purdue Pharma in 2000, court documents reveal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.